Last reviewed · How we verify
Digicor (DIGITOXIN)
At a glance
| Generic name | DIGITOXIN |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | digitoxin |
| Target | Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of Digitoxin to Treat Cystic Fibrosis (PHASE2)
- A Digimed Oncology PharmacoTherapy Registry
- CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Digicor CI brief — competitive landscape report
- Digicor updates RSS · CI watch RSS
- Eli Lilly portfolio CI